Trial informativeness across research practices: initial findings from a mapping exercise

Trial informativeness is influenced by multiple interacting factors across trial design, conduct, and knowledge mobilization, yet how these elements align across current research practices remains unclear. This short communication presents the initial results of a mapping exercise aimed at identifying areas of convergence across three related research strands with the goal of clarifying shared processes and actions that underpin informative trials and the broader research systems in which they operate.

The findings from a rapid review of global insights on trial informativeness, a content analysis of internationally published clinical trial guidance documents, and qualitative interviews with trial stakeholders were compared. Actions and processes to improve trial informativeness that were verbatim or conceptually similar were extracted and organized under a shared framework. Supporting descriptors were compared and synthesized to capture core learnings that consistently appeared across all evidence sources.

Comparison of the three research strands identified a set of 12 good practice actions spanning trial design, conduct, and knowledge mobilization. These actions reflect consistent priorities identified across evidence, guidance, and stakeholder perspectives. Their implementation involves multiple actors across the lifecycle of a trial. All good practice actions identified could apply to funders and/or sponsors, and trial investigators. Other stakeholders include regulatory authorities, patient or community representatives, ethics bodies, policymakers, and so on.

The good practice actions identified to strengthen research systems that contribute to informative trials warrant standalone consideration within a wider mapping exercise, as they address broad drivers of trial quality and support improvements both within and beyond individual studies. Future work should focus on applying, evaluating, and refining these actions to ensure they remain relevant across diverse trial settings and contexts.